medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2011, Number 09-10

<< Back Next >>

Medicina & Laboratorio 2011; 17 (09-10)

Concordance between antinuclear antibody determination by immunofluorescence and line immunoassay

Patricia BC, Rincón COL, César QJ, Helena AB

Language: Spanish
References: 68
Page: 429-443
PDF size: 645.18 Kb.


ABSTRACT

Introduction: Indirect immunofluorescence (IFI) on Hep-2 cells is the test used for screening autoantibodies in connective tissue diseases, while the profile of specific antibodies can be detected by immunometric methods such as solid support line immunoassay (LIA). Objectives: 1) To evaluate the performance of a commercial LIA on serum of patients, and compare it with the determination of antinuclear antibodies by IFI, 2) to describe the profile of the autoantibodies detected by both tests, and 3) to determine the frequency of the different autoantibodies in the evaluated patients. Materials and methods: We included 72 consecutive patients with suspected autoimmune disease that consulted the Pablo Tobón Uribe Hospital in Medellín, Colombia. The samples were processed by IFI and LIA. Results: The homogeneous and speckled patterns were more common in these patients. The most prevalent specific antibodies were the anti-histone, anti-nucleosome and anti-dsDNA; these findings were expected because these are the antibodies associated with the homogeneous pattern, which was the most prevalent. There was a 68,05% concordance between the results by both methods. Conclusions: The low concordance between the two tests, lower than that reported in the literature (90%), could be the result of low pre-test probability of the patients included in the study. The advantages of LIA include that it allows shortening the time of diagnosis and initiation of treatment, its highest sensitivity and specificity, and the ability to individually identify specific antibodies, as well as to detect extractable antibodies that are not identified by IFI.


REFERENCES

  1. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F. Autoantibodies to intracellular antigens: Generation and pathogenetic role. Autoimmun Rev 2011; 10: 503-508.

  2. Scofield RH. Do we need new autoantibodies in lupus? Arthritis Res Ther 2010; 12: 120.

  3. Scofield RH. Genetics of systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol 2009; 21: 448-453.

  4. Jaskowski TD, Wilson AR, Hill HR, Branch WD, Tebo AE. Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? Clin Chim Acta 2009; 410: 19-24.

  5. Stinton LM, Fritzler MJ. A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. Autoimmun Rev 2007; 7: 77-84.

  6. Mohan N, Kerr GS. ANCA-associated small vessel vasculitis: clinical and therapeutic advances. Curr Rheumatol Rep 2010; 12: 406-413.

  7. Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis 2010; 13: e29-31.

  8. Hoffman GS. What does the future hold for clinical studies in vasculitis? Clin Exp Immunol 2011; 164 Suppl 1: 35-38.

  9. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143-1151.

  10. Bardin N, Ragot C, Sanmarco M. Clinical evaluation of a new quantitative enzyme-linked immunosorbent assay for detection of double-stranded DNA autoantibodies. Ann N Y Acad Sci 2007; 1109: 511-518.

  11. Molina-Restrepo JF. El laboratorio en las enfermedades reumáticas autoinmunes. Medicina & Laboratorio 2007; 13: 11-36.

  12. Heidari B, Firouzjahi A, Heidari P, Hajian K. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med 2009; 29: 467-470.

  13. Dugar M, Cox S, Limaye V, Gordon TP, Roberts- Thomson PJ. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010; 86: 79-82.

  14. Albon S, Bunn C, Swana G, Karim Y. Performance of a multiplex assay compared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. J Immunol Methods 2011; 365: 126-131.

  15. Aganovic-Musinovic I, Prljaca-Zecevic L, Subasic D. The incidence of ANA and ETI-dsDNA detected by enzyme immunoassays and indirect immunofluorescence assay (IFA). Med Arh 2010; 64: 68-70.

  16. Mutasim DF. Lupus erythematosus tumidus as a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 163: 230; author reply 231-232.

  17. Mutasim DF. Therapy of autoimmune bullous diseases. Ther Clin Risk Manag 2007; 3: 29-40.

  18. Candon S, Gottenberg JE, Bengoufa D, Chatenoud L, Mariette X. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjogren syndrome: correlation with B-cell biomarkers and disease activity. Ann Rheum Dis 2009; 68: 1208-1212.

  19. Ghedira I, Landolsi H, Mankai A, Fabien N, Jeddi M. [Antihistones antibodies in systemic lupus erythematosus, comparison of three assays: Elisa, dot blot and immunoblot]. Pathol Biol (Paris) 2006; 54: 148-154.

  20. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10: 55-60.

  21. Chien JW, Lin CY. Autoantibodies to dsDNA, Ro/SSA, and La/SSB in systemic lupus erythematosus. Adv Clin Chem 2003; 37: 129-172.

  22. Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjogren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol 2000; 123: 46-57.

  23. Kim S, Kim JH, Lee JH, Kim HS. Evaluation of three automated enzyme immunoassays for detection of anti-cyclic citrullinated peptide antibodies in qualitative and quantitative aspects. Rheumatology (Oxford) 2010; 49: 450-457.

  24. Heinlen LD, McClain MT, Ritterhouse LL, Bruner BF, Edgerton CC, Keith MP, et al. 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One 2010; 5: e9599.

  25. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005; 38: 55-63.

  26. Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 133-139.

  27. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011; 10: 150-154.

  28. Toker E, Yavuz S, Direskeneli H. Anti-Ro/SSA and anti- La/SSB autoantibodies in the tear fluid of patients with Sjogren’s syndrome. Br J Ophthalmol 2004; 88: 384-387.

  29. Salomonsson S, Wahren-Herlenius M. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjogren’s syndrome. Scand J Rheumatol 2003; 32: 79-82.

  30. Meyer O. [Anti-SSA/Ro and anti-SSB/La antibodies. What’s new?]. Ann Med Interne (Paris) 2002; 153: 520-529.

  31. Sato T, Fujii T, Yokoyama T, Fujita Y, Imura Y, Yukawa N, et al. Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 2010; 62: 3730-3740.

  32. Grossmann K, Roggenbuck D, Schroder C, Conrad K, Schierack P, Sack U. Multiplex assessment of nonorgan- specific autoantibodies with a novel microbeadbased immunoassay. Cytometry A 2011; 79: 118-125.

  33. Li J, Luo J, Xu W, Zhang XX, Yuan ZL, Shen B. [Clinical significances of combined detections of autoantibodies in patients with systemic lupus erythematosus]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010; 39: 390-394.

  34. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011; 13: R38.

  35. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? Autoimmun Rev 2010; 9: 756-760.

  36. Van Praet JT, Vander Cruyssen B, Bonroy C, Smith V, Delanghe J, De Keyser F. Validation of a new screening strategy for anti-extractable nuclear antigen antibodies. Clin Exp Rheumatol 2009; 27: 971-976.

  37. Massardo L, Suarez-Almazor ME, Cardiel MH, Nava A, Levy RA, Laurindo I, et al. Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide. J Clin Rheumatol 2009; 15: 203-210.

  38. Maes L, Blockmans D, Verschueren P, Westhovens R, De Beeck KO, Vermeersch P, et al. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma. Clin Chim Acta 2010; 411: 965-971.

  39. Defendenti C, Spina MF, Castiglione A, Atzeni F, Miadonna A, Saudelli M, et al. [Alveolar hemorrhage in pulmonary-renal syndrome anti-SCL/70 and anti- MPO-ANCA positive]. Recenti Prog Med 2009; 100: 361-364.

  40. Dellavance A, Gallindo C, Soares MG, da Silva NP, Mortara RA, Andrade LE. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 2009; 48: 632-637.

  41. Shinjo SK, Levy-Neto M. Anti-Jo-1 antisynthetase syndrome. Rev Bras Reumatol 2010; 50: 492-500.

  42. Vincze M, Molnar PA, Zilahi E, Kapitany A, Dezso B, Takacs I, et al. Primary lung adenocarcinoma associated with anti-Jo-1 positive polymyositis. Joint Bone Spine 2011; 78: 209-211.

  43. Haussermann A, Gillissen A, Seidel W. [The anti-Jo-1 syndrome - a specific form of myositis with interstitial lung disease]. Pneumologie 2010; 64: 496-503.

  44. Servais G, Karmali R, Guillaume MP, Badot V, Duchateau J, Corazza F. Anti DNA antibodies are not restricted to a specific pattern of fluorescence on HEp2 cells. Clin Chem Lab Med 2009; 47: 543-549.

  45. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009; 19: 219-228.

  46. Keefe D, Hess D, Bosco J, Tzartos S, Powell J, Lamsa J, et al. A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines. Cytometry B Clin Cytom 2009; 76: 206-212.

  47. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49: 2243-2254.

  48. Sarkar RN, Banerjee S, Dey S, Saha A, Bhattacharjee P, Banerjee TK, et al. Haematological presentation of systemic lupus erythematosus. J Assoc Physicians India 2009; 57: 767-768.

  49. Fujiwara K, Yasui S, Yokosuka O. Efforts for making the diagnosis of acute onset autoimmune hepatitis. Hepatology 2011.

  50. Mayo MJ. Management of autoimmune hepatitis. Curr Opin Gastroenterol 2011; 27: 224-230.

  51. Chapaeva NN, Trifonova MA, Gromov AA. [The hemostatic system in patients with antiphospholipid syndrome]. Klin Lab Diagn 2010: 51-55.

  52. Anderson JA, Weitz JI. Hypercoagulable states. Clin Chest Med 2010; 31: 659-673.

  53. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011; 37: 267-274.

  54. Palchevskiy V, Hashemi N, Weigt SS, Xue YY, Derhovanessian A, Keane MP, et al. Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis. Fibrogenesis Tissue Repair 2011; 4: 10.

  55. Casciola-Rosen L. Histidyl-transfer RNA synthetase: a key participant in idiopathic inflammatory myopathies. Arthritis Rheum 2011; 63: 331-333.

  56. Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. Autoimmunity 2010; 43: 344-352.

  57. Trivedi S, Zang Y, Culpepper S, Rosenbaum E, Fernandez I, Martinez L, et al. T cell vaccination therapy in an induced model of anti-RNP autoimmune glomerulonephritis. Clin Immunol 2010; 137: 281-287.

  58. Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med 2002; 156: 356-361.

  59. Flores JC, Alvo M, Borja H, Morales J, Vega J, Zuniga C, et al. [Clinical guidelines on identification, management and complications of chronic kidney disease]. Rev Med Chil 2009; 137: 137-177.

  60. Niang A, Dial C, Ka EF, Leye A, Pouye A, Ka MM, et al. [Nephrotic syndrom with focal and segmental glomerulosclerosis in Dakar: epidemiological and clinicopathological characteristics (about 134 cases)]. Dakar Med 2008; 53: 45-51.

  61. Pourmand N, Blomberg S, Ronnblom L, Karlsson-Parra A, Pettersson I, Wahren-Herlenius M. Ro 52kD autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol 2000; 29: 116-123.

  62. Thomson KF, Murphy A, Goodfield MJ, Misbah SA. Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells? J Clin Pathol 2001; 54: 413.

  63. Toubert ME, Chevret S, Cassinat B, Schlageter MH, Beressi JP, Rain JD. From guidelines to hospital practice: reducing inappropriate ordering of thyroid hormone and antibody tests. Eur J Endocrinol 2000; 142: 605-610.

  64. Ramos Soler D, Mayordomo Aranda E, Calatayud Blas A, Rubio Briones J, Solsona Narbon E, Llombart Bosch A. [Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology]. Actas Urol Esp 2006; 30: 345-352.

  65. Ramos-Payan R, Aguilar-Medina M, Estrada-Parra S, Gonzalez YMJA, Favila-Castillo L, Monroy-Ostria A, et al. Quantification of cytokine gene expression using an economical real-time polymerase chain reaction method based on SYBR Green I. Scand J Immunol 2003; 57: 439-445.

  66. Phan TG, Ng WW, Bird D, Smithers K, Wong V, Gallagher K, et al. High-quality, cost-effective strategy for detection of autoantibodies to extractable nuclear antigens. Clin Diagn Lab Immunol 2001; 8: 471-474.

  67. Skogh T, Dahlgren C, Holmgren K, Peen E, Stendahl O. Anti-granulocyte antibodies (C-ANCA, P-ANCA, GS-ANA) studied by confocal scanning laser fluorescence microscopy, ELISA, and chemiluminescence techniques. Scand J Immunol 1991; 34: 137-145.

  68. Eissfeller P, Sticherling M, Scholz D, Hennig K, Luttich T, Motz M, et al. Comparison of different test systems for simultaneous autoantibody detection in connective tissue diseases. Ann N Y Acad Sci 2005; 1050: 327-339.




2020     |     www.medigraphic.com